Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 407
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00252642 | Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C | ||
| NCT01259856 | Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | ||
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | ||
| NCT03721484 | CINtec PLUS Triage in HPV Primary Screening | ||
| NCT05017142 | Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | ||
| NCT04487756 | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer | ||
| NCT01332929 | Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis | ||
| NCT01220596 | Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B. | ||
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | ||
| NCT00620269 | Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III | ||
| NCT03802604 | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | ||
| NCT04661358 | Fenofibrate for Prevention of DR Worsening | ||
| NCT05300282 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients | ||
| NCT01368848 | Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC) | ||
| NCT05075538 | COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 | ||
| NCT01697267 | Rituximab Vasculitis Maintenance Study | ||
| NCT04611867 | Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay) | ||
| NCT02636452 | Cardiopulmonary Exercise Testing in Interstitial Lung Disease | ||
| NCT00752336 | Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation | ||
| NCT01817452 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol | ||
| NCT00824993 | Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients | ||
| NCT06191068 | Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With Hemophilia | ||
| NCT03831490 | Study for Improving Maternal, Pregnancy and Child Outcomes | ||
| NCT00562770 | Oral Valganciclovir Versus Valacyclovir | ||
| NCT01126866 | Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy | ||
| NCT04292574 | UK SMA Patient Registry | ||
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer | ||
| NCT00427375 | Local Excision in Downstaged Rectal Cancer | ||
| NCT01472029 | Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | ||
| NCT04708639 | Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | ||
| NCT01752192 | Teledi@Log - Tele-rehabilitation of Heart Patients | ||
| NCT04059081 | A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment | ||
| NCT01450137 | Tocilizumab for Patients With Giant Cell Arteritis | ||
| NCT01723111 | Impact of Dialysis Modality on Hepcidin and Iron Metabolism | ||
| NCT04387890 | Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers | ||
| NCT03474094 | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy | ||
| NCT04888221 | Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement | ||
| NCT00476164 | Study of Rituximab to Treat Chronic Renal Transplant Rejection | ||
| NCT01195298 | Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer | ||
| NCT02562378 | T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | ||
| NCT04759248 | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer | ||
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | ||
| NCT00450203 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | ||
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer | ||
| NCT00275132 | Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | ||
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | ||
| NCT05470595 | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung | ||
| NCT02558816 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients | ||
| NCT01015352 | Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) | ||
| NCT02790645 | Telemedicine Program in Type 1 Diabetes and CSII |
